Sorry, you need to enable JavaScript to visit this website.
We are focused on Precision Medicine as an approach to discovering and developing medicines and vaccines that deliver superior outcomes for patients, by integrating clinical and molecular information to understand the biological basis of disease. This effort leads to better selection of disease targets and identification of patient populations that demonstrate improved clinical outcomes.

Pfizer is interested in establishing alliances to develop and/or access:

  • Patient cohorts with high quality longitudinal molecular and phenotypic data and/or DNA and appropriately-consented, IRB-approved tissue samples in diseases of interest to Pfizer for
    • clinical trials
    • data mining
    • biomarker studies
    • genetic and pharmaco-genomic studies
  • Systems Biology/Pharmacology
    • Databases with high quality treatment and disease outcomes associated with genetic, as well as molecular (metabolomic, proteomic, transcriptomic, epigenetic, clinical chemistry markers) or functional measures in particular imaging data
    • Databases of searchable eQTLs, pQTLs across tissues
    • Disease biology guided combination therapy design platforms
    • Systems biology approaches and proven in silico tools to evaluate pharmacological perturbation and elucidate mechanisms of in vivo toxicity
    • Mining of data for correlation and understanding of causality
  • Breakthrough diagnostic technologies that also are highly quantitative, require minimal specimen/ tissue, offer quick turnaround time and can be multiplexed.  This will include but not limited to:
    • Near-patient Point-of-Care technologies
    • Next Generation Sequencing technologies
    • Circulating cells
    • Circulating and urinary cell-free nucleic acids
    • Antigen receptor sequencing
    • Microbiome, including virome characterization
  • In vivo imaging technologies (including MRI, PET, CT, optical imaging technologies, imaging agents, genetically encoded tags, etc.,) with particular interest in:
    • Imaging agents for small and large molecule compound distribution studies
    • Imaging agents monitoring physiology mechanisms and disease
    • Analytical tools and technologies
  • Biospecimen Analysis
    • Circulating tumor cell and Nucleic Acid quantification and analysis
    • Multiplexed flow cytometry for leukocyte analysis
    • Automated IHC for tissue analysis (cancer, safety)
    • Advanced ADME — related genotyping
    • 3D cell models for safety and efficacy assessment that ideally incorporate genetic diversity
  • Physiological Biomarkers
    • Technologies adding precision to pain management and treatment in pre-clinical and clinical studies
    • EEG-based biomarker for assessment of central pharmacology
  • iPS cell resources and technologies to generate iPS cells that may be used to enable Precision Medicine strategies
    • Validated cell differentiation protocols
    • iPS cells derived from sub populations with specific genotypic/phenotypic data
    • Technology to create iPS cells in a rapid and reproducible fashion without insertional approaches

External R&D Innovation Contact: Paul.E.Young or Melissa Fitzgerald